Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria ...Middle East

AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and Drug...

Hence then, the article about aeglea biotherapeutics receives fda rare pediatric disease designation for acn00177 for the treatment of homocystinuria was published today ( Tuesday 01/12/2020 - 03:46 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria )

Also on site :

• Ann Godoff, Penguin Press Founder and Editor, Dies at 76
• Megan Thee Stallion Has One Question for Juvenile About Their Rumored ‘B.B.B.’ Remix: ‘When You Gonna Drop It?’
• WI vs SA Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- ICC T20 World Cup 2026, Match 47